MEGA-C-SODIUM INJ 250MG/ML 250 MG — DIN 00525189
SODIUM ASCORBATE : 250 MG · KRIPPS PHARMACY LTD. · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is MEGA-C-SODIUM INJ 250MG/ML?
MEGA-C-SODIUM INJ 250MG/ML 250 MG contains SODIUM ASCORBATE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00525189, held by KRIPPS PHARMACY LTD., supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 18-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
Is there a generic Vitamins in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Vitamins, across 9 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 3 | 2 | MULTI 1000, MULTI 12 INJECTION, MULTI-11 | Sourceable in Canada |
| AVENTIS PHARMA INC | 2 | 0 | M.V.I. 12, M.V.I. PAEDIATRIC | No marketed DIN |
| DAVID BULL LABORATORIES (PTY) LTD. | 1 | 0 | MULTI-VITAMINS FOR INFUSION LIQ | No marketed DIN |
| KRIPPS PHARMACY LTD. | 1 | 0 | MEGA-C-SODIUM INJ 250MG/ML | No marketed DIN |
| LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | 1 | 0 | MVC 9 PLUS 3 INJ | No marketed DIN |
| SABEX INC | 1 | 0 | MULTI-12 PEDIATRIC | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Vitamins |
|---|---|
| ATC code | B05XC |
| AHFS class | 88:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00525189 |
|---|---|
| DIN (unpadded, as printed on some documents) | 525189 |
| Brand name | MEGA-C-SODIUM INJ 250MG/ML |
| Generic / active ingredient | SODIUM ASCORBATE : 250 MG |
| Market authorization holder | KRIPPS PHARMACY LTD. |
| Health Canada schedule | Ethical |
| ATC code | B05XC |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05XC |
| Current status | DORMANT |
| Status date | 18-Aug-2018 |
| Original market date | 1981-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MULTI 1000 | 1.2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 00586315 |
| MULTI 12 INJECTION | 0.72 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 02100606 |
| M.V.I. 12 | 660 UNIT | LIQUID | AVENTIS PHARMA INC | CANCELLED POST MARKET | 01927841 |
| M.V.I. PAEDIATRIC | 1.2 MG | LIQUID | AVENTIS PHARMA INC | CANCELLED POST MARKET | 01927833 |
| MULTI-11 | 8 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02244696 |
| MULTI-12 PEDIATRIC | 1 MCG | LIQUID | SABEX INC | CANCELLED POST MARKET | 02236829 |
| MULTI-VITAMINS FOR INFUSION LIQ | 200 UNIT / 10 ML | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 01904191 |
| MVC 9 PLUS 3 INJ | 15 MG / 5 ML | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | 01945637 |
2 · Same class — other molecules in ATC B05XC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Vitamins | M.V.I. 12 · M.V.I. PAEDIATRIC · MEGA-C-SODIUM INJ 250MG/ML · MULTI 1000 · +5 more | 9 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05XA | Calcium Chloride · Calcium Gluconate · Combinations Of Electrolytes · Electrolytes In Comb With Other Drugs · Magnesium Sulphate · +9 more | 136 | 51 |
| B05XX | Trometamol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MEGA-C-SODIUM INJ 250MG/ML called?
The same molecule, Vitamins, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FruitiVits | Latin | Australia |
| Paediatric Seravit | Latin | Australia |
| Phlexy-Vits | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.